Recombinant human serum albumin (rHSA)
Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor-blood supply and viral-contamination risk since the 1940s — and the first rice-derived rHSA for injection has been approved by FDA/EMA/PMDA. The global rHSA market stands at USD 166 million.
Procurement category: contract manufacturing. Bioecon selects providers and organises the work in this category to the customer's brief. Catalogue-level entry: the specific manufacturer, configuration and specification are determined at the enquiry stage. Price — on request.
| Category slug | contract-manufacturing |
|---|---|
| Cluster | specialty-fine-chem |
| Article | recombinant-human-serum-albumin |
| Identifier | bio.svc.recombinant-human-serum-albumin.contract-manufacturing |
| CPV | 33651600, 33652300 |
| OKPD2 | 21.20 |
| NAICS | 325411, 325412, 325414 |
| UNSPSC | 41110000 |
| CHINA CP | A0321 |
Every item is a procurement category, not a named manufacturer's product. Bioecon is a single seller and holds no stock: supplier selection, configuration and specification are settled at enquiry, and the price is by quote.